Current Therapies for Lupus Nephritis in an Ethnically Heterogeneous Cohort

Abstract

After controlling for the fact that less severe nephritis is preferentially treated with MMF, we found overall that response to MMF was superior to CYC. In this US population, ethnicity was observed to have an influence on response.

Rituximab and lupus: Good in real life, bad in controlled trials. comment on the article by Lu et al

“…However, the majority of patients from recent uncontrolled studies were European (1,6,7,9,11,12). This ethnicity is important because some studies have suggested a variable therapeutic response to the main immunosuppressive agents in different ethnic groups (13).…”

Treatment of Lupus Nephritis by Mycophenolate Mofetil

“…In humans, it was initially used as an induction treatment and subsequently for maintenance therapy, particularly in patients with proliferative LN [21][22][23][24] . Recently it was shown that MMF is also beneficial in membranous LN [25][26][27] . Our group of 35 patients included various LN types, most of whom (i.e.…”

Treatment of Idiopathic Membranous Nephropathy

“…On the basis of studies of other primary glomerulopathies, Asian ethnicity may be associated with a relatively favorable prognosis and increased responsiveness to certain immunosuppressive regimens. [77][78][79] A trial from the Netherlands compared outcomes of 32 IMN patients treated with 1 year of MMF plus corticosteroids with historical matched controls treated with oral cyclophosphamide plus corticosteroids for 1 year. 75 Patients were considered at high risk for progressive disease with reduced GFR at baseline (median approximately 40 ml/min) and high-grade proteinuria.…”